Needham & Company LLC Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $139.00

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective cut by Needham & Company LLC from $148.00 to $139.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

RYTM has been the topic of several other reports. Royal Bank Of Canada assumed coverage on Rhythm Pharmaceuticals in a research report on Wednesday, February 18th. They issued an “outperform” rating and a $145.00 target price on the stock. Wells Fargo & Company lifted their price target on Rhythm Pharmaceuticals from $129.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Morgan Stanley reissued an “overweight” rating and issued a $150.00 price objective on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. The Goldman Sachs Group raised their price objective on Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Finally, Citizens Jmp lifted their target price on Rhythm Pharmaceuticals from $141.00 to $167.00 and gave the stock a “market outperform” rating in a report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Rhythm Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $133.71.

Rhythm Pharmaceuticals Stock Down 5.4%

Shares of Rhythm Pharmaceuticals stock opened at $92.73 on Thursday. The company has a 50 day moving average price of $103.90 and a 200 day moving average price of $103.54. The firm has a market capitalization of $6.19 billion, a P/E ratio of -29.82 and a beta of 2.00. Rhythm Pharmaceuticals has a 52 week low of $45.90 and a 52 week high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.06. The company had revenue of $57.25 million for the quarter, compared to the consensus estimate of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 378.31%. Rhythm Pharmaceuticals’s revenue was up 36.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.72) EPS. As a group, research analysts anticipate that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insider Transactions at Rhythm Pharmaceuticals

In related news, insider Pamela J. Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the transaction, the insider directly owned 20,814 shares in the company, valued at approximately $2,310,354. This trade represents a 13.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Hunter C. Smith sold 4,385 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at $11,190,445.12. The trade was a 3.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 25,003 shares of company stock valued at $2,589,015 in the last quarter. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in RYTM. EverSource Wealth Advisors LLC lifted its stake in shares of Rhythm Pharmaceuticals by 303.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after purchasing an additional 200 shares during the period. Smartleaf Asset Management LLC grew its position in Rhythm Pharmaceuticals by 97.2% during the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after buying an additional 141 shares during the period. Farther Finance Advisors LLC increased its holdings in Rhythm Pharmaceuticals by 1,110.3% in the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock valued at $35,000 after buying an additional 322 shares in the last quarter. Optiver Holding B.V. raised its position in shares of Rhythm Pharmaceuticals by 65.2% in the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after acquiring an additional 144 shares during the period. Finally, SBI Securities Co. Ltd. raised its position in shares of Rhythm Pharmaceuticals by 73.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after acquiring an additional 145 shares during the period.

More Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat estimates: EPS of $-0.73 vs. consensus of $-0.79 and revenue of $57.25M (y/y revenue +36.9%). The beat supports commercial traction for IMCIVREE. Zacks: Rhythm Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst upgrade/target raise: Citizens JMP raised its price target to $176 and kept a “market outperform” rating, signaling strong upside to Street models. Benzinga: Citizens JMP raises PT
• Positive Sentiment: Analyst raise: Guggenheim lifted its target to $143 and maintained a “buy” rating, adding another constructive analyst signal. Benzinga: Guggenheim raises PT
• Positive Sentiment: Near‑term clinical/regulatory catalysts remain: PDUFA goal date for the sNDA in acquired hypothalamic obesity on March 20, plus March topline readouts from Phase 3 programs (EMANATE and a Japanese cohort) that could significantly re‑rate the story. GlobeNewswire: Rhythm Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst trim but still constructive: Wells Fargo cut its target to $136 but kept an “overweight” rating, signaling continued confidence despite a smaller upside. Benzinga: Wells Fargo lowers PT
• Neutral Sentiment: Needham lowered its target to $139 but maintained a “buy”—another sign that sell‑side views remain broadly positive even as models are adjusted. TickerReport: Needham lowers PT
• Negative Sentiment: Large near‑term spending guide: Rhythm told investors it expects $385M–$415M in 2026 non‑GAAP operating expenses as hypothalamic‑obesity (HO) launch preparations accelerate — higher burn that may pressure margins and cash runway in the near term. Seeking Alpha: Rhythm anticipates $385M–$415M in 2026 non‑GAAP operating expenses

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.